Metabolic Dysfunction-Associated Steatohepatitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Metabolic Dysfunction-Associated Steatohepatitis (US)

The treatment of metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has enormous potential for growth owing to the disease’s prevalence and the limited number of approved agents. The treatment algorithm for MASH in the United States combines lifestyle modification, pharmacotherapy, and optimizing the management of comorbidities. Recently, the FDA approved the first-ever drug for MASH: resmetirom (Rezdiffra). MASH patients with comorbidities such as obesity and type 2 diabetes may also benefit from GLP-1 receptor agonists, which are being evaluated for their potential to treat MASH in addition to their established roles in managing weight and glycemic levels. We use claims data to examine the treatment of MASH in the United States among both newly diagnosed and recently treated patients.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MASH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MASH patients?
• How has resmetirom (Rezdiffra) been integrated into the treatment algorithm, and what is its source of business?
• What percentage of MASH patients receive drug therapy within a year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
• What percentage of MASH patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Markets covered: United States

Key companies: Madrigal Pharma, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Akero Therapeutics, Inventiva Pharma, Sagimet Biosciences, 89bio, Viking Therapeutics

Key drugs: Resmetirom, GLP-1 receptor agonists, SGLT-2 inhibitors, statins

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses